Spyre Therapeutics Inc. (SYRE) can make a big difference with a little luck

With 0.77 million shares changed hands, the volume of the stock remained heavier than its average volume of 3.9 shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $24.58 whereas the lowest price it dropped to was $23.56. The 52-week range on SYRE shows that it touched its highest point at $28.66 and its lowest point at $2.66 during that stretch. It currently has a 1-year price target of $30.33. Beta for the stock currently stands at 2.84.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SYRE was down-trending over the past week, with a drop of -6.95%, but this was up by 8.22% over a month. Three-month performance surged to 146.91% while six-month performance rose 82.55%. The stock gained 69.35% in the past year, while it has gained 11.29% so far this year. A look at the trailing 12-month EPS for SYRE yields -78.22 with Next year EPS estimates of -1.94. For the next quarter, that number is -0.71. This implies an EPS growth rate of 69.67% for this year and 74.22% for next year.


Float and Shares Shorts:

At present, 36.06 million SYRE shares are outstanding with a float of 34.22 million shares on hand for trading. On Jan 31, 2024, short shares totaled 0.71 million, which was 1.97% higher than short shares on Dec 29, 2023. In addition to Mr. James Paul Kastenmayer J.D., Ph.D. as the firm’s Consultant, Dr. Cameron Turtle DPHIL, Ph.D. serves as its CEO, Principal Executive Officer & Director.

Institutional Ownership:

Through their ownership of 51.49% of SYRE’s outstanding shares, institutional investors have majority control over the company.


Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SYRE since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential. With SYRE analysts setting a high price target of $44.00 and a low target of $12.00, the average target price over the next 12 months is $30.33. Based on these targets, SYRE could surge 83.72% to reach the target high and fall by -49.9% to reach the target low. Reaching the average price target will result in a growth of 26.64% from current levels.

Summary of Insider Activity:

Insiders traded SYRE stock several times over the past three months with 0 Buys and 0 Sells. In these transactions, 0 shares were bought while 0 shares were sold. The number of buy transactions has remained unchanged to 0 while that of sell transactions has remained unmoved to 0 over the past year. The total number of shares bought during that period was 0 while 0 shares were sold.